BridgeBio Pharma, Inc. (BBIO)

In Q1 2026, BridgeBio reported total revenues of $194.5 million, exceeding forecasts, driven by U.S. Attruby net product revenue, which represented a 392% year-over-year growth, but reported an EPS of -$0.84, missing consensus estimates. The Board of Directors authorized a share repurchase program of up to $500 million. The company submitted its first of three planned NDAs to the FDA for BBP-418 in LGMD2I/R9, with NDAs for encaleret and oral infigratinib planned for 1H 2026 and Q3 2026, respectively. BridgeBio announced inducement equity grants for new employees in April and May 2026 and management participated in investor fireside chats at healthcare conferences in May–June 2026. As of May 6, 2026, the share price was $68.08, representing a 90.06% increase over the past year, but decreased by 11.9% from the beginning of 2026 to May 9, 2026.

The provided information primarily discusses the seasonality of BridgeBio Pharma's stock price rather than the demand seasonality for its products and services. June has shown the highest probability of positive returns for BBIO stock at 83.33%, while May may not be an ideal month to invest, with a 28.57% probability of a positive return. The demand for its treatments is likely driven by patient diagnosis and medical need rather than typical seasonal consumer patterns.

BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering transformative medicines for genetic diseases and cancers with clear genetic drivers. The company's pipeline spans from early research to advanced clinical trials, focusing on Mendelian disorders, oncology, and gene therapy. Key products include Attruby for transthyretin-mediated amyloidosis, NULIBRY for molybdenum cofactor deficiency, low-dose Infigratinib for achondroplasia and hypochondroplasia, Encaleret for Autosomal Dominant Hypocalcemia Type 1 and Chronic Hypoparathyroidism, BBP-418 for Limb Girdle Muscular Dystrophy Type 2I, and BBP-812 for Canavan disease.

BridgeBio Pharma, Inc. is headquartered in Palo Alto, California, and has expanded its clinical and research activities across North America, Europe, and Asia. Attruby has received approvals in multiple regions, including the US, EU, Japan, UK, Switzerland, and Brazil. The company has over 2000 patients enrolled in its clinical trials globally.

BridgeBio Pharma's brand reputation has been positively influenced by its strong commercial performance and advancements in its clinical pipeline. The successful commercialization of Attruby and consistent progress in advancing its late-stage product candidates have enhanced its reputation as an innovative biopharmaceutical company.

Approximately 98.56% of BridgeBio Pharma stock is held by institutional shareholders, with major holders including Vanguard Group Inc and BlackRock, Inc. Insiders own approximately 54.87% of the company's stock, with Kkr Group Partnership LP being the largest individual shareholder. Retail investors hold a smaller percentage of the stock.